Overview

Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy

Status:
Withdrawn

Trial end date:
2015-06-01

Target enrollment:
0

Participant gender:
All

Summary

This will be a 4-way comparison to prospectively evaluate the efficacy and patient tolerability of four commercially available bowel preparations among patients undergoing colonoscopy for screening and surveillance in a single tertiary academic medical center.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

Cathartics
Citric Acid
Magnesium Oxide
Magnesium Sulfate
Sodium sulfate

Criteria

Inclusion Criteria:

1. Age 18 years or greater

2. Ability to understand and complete questionnaires

3. Ability to speak and read English

4. Willingness to participate in study

5. Colonoscopy is being performed for routine screening (i.e. no prior personal history
of polyps or cancer) or surveillance (i.e. follow up for a personal history of polyps)
purposes

Exclusion Criteria:

1. Previous bowel resection of any kind (small or large bowel)

2. End stage renal disease (ESRD)

3. Contraindication to bowel purgative

4. Necessity for inpatient admission to receive bowel preparation for any reason

5. Currently taking any narcotic/opiate pain or anticholinergic medication (since these
may predispose to higher colon stool burden at baseline)

6. Currently taking stool softeners (e.g. Miralax, Amitiza, Linzess, lactulose) or
stimulant laxatives (e.g. Dulcolax)

7. Subject did not follow appropriate dosing instructions for bowel purgative

8. Colonoscopy is being performed to evaluate a clinical symptom such as rectal bleeding,
constipation, abdominal pain, or diarrhea

9. History of colon polyposis syndrome

10. Personal history of inflammatory bowel disease

11. History of inadequate colon preparation on any prior colonoscopies

12. Patient is pregnant